Abstract: A multi-use drug delivery device for extended use, wherein the multi-use drug delivery device comprising a multi-use main portion (310) and a single-use flow conducting device (360) adapted for conducting drug to the subcutaneous tissue of a subject, wherein the change from a connected configuration to an unconnected configuration of the main portion and the flow conducting device is through the intermediate configuration. The intermediate configuration comprises an equalizing channel defining an equalizing flow path (304) different from an unintended flow path (303).

Abstract: An assembly includes a sealed drug reservoir unit, a subcutaneous flow conducting device in the form of a needle unit or an infusion set, and a flow communication unit. The flow communication unit includes a proximal hollow needle adapted to penetrate a needle-penetrable septum of the reservoir, a first flow-way inflow communication with the proximal needle and comprising a pressure-controlled valve, a second flow-way in flow communication with the first flow-way, an amount of preservative arranged to react with a substance received by the second flow-way, and distal flow communication structure adapted to provide flow communication between the second flow-way and the needle unit. The valve is controlled to open when the reservoir is pressurized, the preservative being provided to react with substances introduced to the second flow way via the needle unit.

Abstract: A multi-use injection device (100) for multiple subcutaneous injections, wherein the injection device comprises a device main portion (110) and a multi-use needle unit (150) adapted to prevent unintended introduction of living microorganisms into a reservoir (114) of the device main portion during use of the injection device, and thereby promote bacteriostasis of a multiple-use drug preparation (115) during a use period with multiple injections. The drug delivery device (100) is adapted to enable multiple injections, without accidentally introducing living microbial contaminations into the reservoir during use, by adapting the multi-use needle to: (i) sterilize contaminations introduced into the distal needle after each exposure of a distal injection needle (156), (ii) restrict diffusion and flow from the distal needle (156) to the reservoir (114) with a valve (170), (iii), and by allowing the needle unit to remain mounted in the in-use configuration during the use period with multiple injections.

Abstract: A multi-use drug delivery device for extended use, wherein the multi-use drug delivery device comprising a multi-use main portion (310) and a single-use flow conducting device (360) adapted for conducting drug to the subcutaneous tissue of a subject, wherein the change from a connected configuration to an unconnected configuration of the main portion and the flow conducting device is through the intermediate configuration. The intermediate configuration comprises an equalizing channel defining an equalizing flow path (304) different from an unintended flow path (303).

Abstract: An assembly comprises a sealed drug reservoir unit, a subcutaneous flow conducting device in the form of a needle unit or an infusion set, and a flow communication unit. The flow communication unit comprises a proximal hollow needle adapted to penetrate a needle-penetrable septum of the reservoir, a first flow-way inflow communication with the proximal needle and comprising a pressure-controlled valve, a second flow-way in flow communication with the first flow-way, an amount of preservative arranged to react with a substance received by the second flow-way, and distal flow communication means adapted to provide flow communication between the second flow-way and the needle unit. A combined flow way can be established between the reservoir and the needle unit via the first and second flow-ways when the units are connected. The valve is controlled to open when the reservoir is pressurized, the preservative being provided to react with substances introduced to the second flow way via the needle unit.

Abstract: The present invention relates to pharmaceutical compositions comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised in that the GLP-1:divalent metal molar ratio is 1:>2. The compositions of the invention are particularly useful in the treatment of diabetes.

Abstract: The present invention relates to compositions and particles comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised that the particle comprises a core and a surrounding layer, the core comprising the GLP-1 compound and the divalent metal, and the surrounding layer comprising the polycationic compound. The invention is particularly useful for the treatment of metabolic diseases, including diabetes.

Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

Abstract: Conjugates exhibiting growth hormone (GH) activity and comprising at least one non-polypeptide moiety covalently attached to a GH polypeptide, the amino acid sequence of which differs from that of wildtype human GH in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule such as PEG or a sugar moiety. The conjugate finds particular use in therapy.

Abstract: A parenterally administrable, biodegradable microparticle preparation containing a biologically active substance which, during the first 24 hours after injection, exhibits a release of the active substance that is less than 25% of the total release, determined from a concentration-time curve in the form of the ratio between the area under the curve during the said first 24 hours and the total area under the curve in question

Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

Abstract: The invention relates to interferon compositions, such as pharmaceutical interferon compositions and methods of their preparation. In particular it relates to stabilized compositions comprising an interferon molecule and a sulfoalkyl ether cyclodextrin derivative.